Crizotinib demonstrated potent antitumor activity in patients with NSCLC harboring echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion or ROS1 rearrangement, which led to FDA approval for its clinical use13–15,17. This evidence concerns the gene EML4 and non-small cell lung carcinoma.